UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 48

Sortiert nach

Development and Validation of a Tool Integrating the 21-Gene Recurrence Score and Clinical-Pathological Features to Individualize Prognosis and Prediction of Chemotherapy Benefit in Early Breast Cancer

Journal of clinical oncology, 2021-02, Vol.39 (6), p.557-564

2021

Volltextzugriff (PDF)

Extensions of the absolute standardized hazard ratio and connections with measures of explained variation and variable importance

Lifetime data analysis, 2020-10, Vol.26 (4), p.872-892

Crager, Michael R.

2020

Volltextzugriff (PDF)

Reply to K. Ando et al

Journal of clinical oncology, 2021-06, Vol.39 (17), p.JCO2100424-1948

2021

Volltextzugriff (PDF)

Long-term safety of a novel antianginal agent in patients with severe chronic stable angina : The Ranolazine Open Label Experience (ROLE)

Journal of the American College of Cardiology, 2007-03, Vol.49 (10), p.1027-1034

2007

Volltextzugriff (PDF)

Population-based estimate for the correlation of the Oncotype Dx Breast Recurrence Score® result and Ki-67 IHC MIB-1 pharmDx in HR+, HER2-, node-positive early breast cancer

Breast cancer research : BCR, 2022-11, Vol.24 (1), p.74-74, Article 74

2022

Volltextzugriff (PDF)

Risk of Recurrence and Chemotherapy Benefit for Patients With Node-Negative, Estrogen Receptor–Positive Breast Cancer: Recurrence Score Alone and Integrated With Pathologic and Clinical Factors

Journal of clinical oncology, 2011-11, Vol.29 (33), p.4365-4372

2011

Volltextzugriff (PDF)

Validating the association of adverse pathology with distant metastasis and prostate cancer mortality 20-years after radical prostatectomy

Urologic oncology, 2022-03, Vol.40 (3), p.104.e1-104.e7

2022

Volltextzugriff (PDF)

Gene identification using true discovery rate degree of association sets and estimates corrected for regression to the mean

Statistics in medicine, 2010-01, Vol.29 (1), p.33-45

Crager, Michael R.

2010

Volltextzugriff (PDF)

Patient-specific Meta-analysis of 2 Clinical Validation Studies to Predict Pathologic Outcomes in Prostate Cancer Using the 17-Gene Genomic Prostate Score

Urology (Ridgewood, N.J.), 2016-03, Vol.89, p.69-75

2016

Volltextzugriff (PDF)

Prospective Calculation of Identification Power for Individual Genes in Analyses Controlling the False Discovery Rate

Genetic epidemiology, 2012-12, Vol.36 (8), p.839-847

Crager, Michael R.

2012

Volltextzugriff (PDF)

21-Gene assay as predictor of chemotherapy benefit in HER2-negative breast cancer

NPJ breast cancer, 2018-11, Vol.4 (1), p.37-6, Article 37

2018

Volltextzugriff (PDF)

GPS Assay Association With Long-Term Cancer Outcomes: Twenty-Year Risk of Distant Metastasis and Prostate Cancer-Specific Mortality

JCO precision oncology, 2021, Vol.5

2021

Volltextzugriff (PDF)

Whole transcriptome RNA-Seq analysis of breast cancer recurrence risk using formalin-fixed paraffin-embedded tumor tissue

PloS one, 2012-07, Vol.7 (7), p.e40092-e40092

2012

Volltextzugriff (PDF)

Adjusting for covariates in evaluating markers for selecting treatment, with application to guiding chemotherapy for treating estrogen-receptor-positive, node-positive breast cancer

Contemporary clinical trials, 2017-12, Vol.63, p.30-39

2017

Volltextzugriff (PDF)

Patient-specific meta-analysis for risk assessment using multivariate proportional hazards regression

Journal of applied statistics, 2014-01, Vol.41 (12), p.2676-2695

2014

Volltextzugriff (PDF)

Generalizing the standardized hazard ratio to multivariate proportional hazards regression, with an application to clinical~genomic studies

Journal of applied statistics, 2012-02, Vol.39 (2), p.399-417

Crager, Michael R.

2012

Volltextzugriff (PDF)

Separate Class True Discovery Rate Degree of Association Sets for Biomarker Identification

Journal of biopharmaceutical statistics, 2014-01, Vol.24 (5), p.1022-1034

2014

Volltextzugriff (PDF)

Cytomegalovirus (CMV) DNA Load Is an Independent Predictor of CMV Disease and Survival in Advanced AIDS

Journal of Virology, 1999-08, Vol.73 (8), p.7027-7030

1999

Volltextzugriff (PDF)

Abstract GS4-10: Development and validation of a tool integrating the 21-gene recurrence score and clinicopathlogic features to individualize prognosis for distant recurrence and prediction of absolute chemotherapy benefit in early breast cancer

Cancer research (Chicago, Ill.), 2021-02, Vol.81 (4_Supplement), p.GS4-10-GS4-10

2021

Volltextzugriff (PDF)

Correlation of the oncotype DX breast recurrence score and the ki-67 IHC MIB-1 pharmDX score in HR+, HER2-, node-positive early breast cancer

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.e12556-e12556

2022

Volltextzugriff (PDF)

Interval Estimation of the Absolute Risk of an Event with Competing Risks Using Proportional Regression of Cause-Specific Hazards

American journal of applied mathematics (Print), 2022, Vol.10 (2), p.59

2022

Volltextzugriff (PDF)

Abstract GS4-03: Validation of the clinical treatment score post 5 years (CTS5) in women with hormone receptor positive, HER2-negative, node-negative disease from the TAILORx study

Cancer research (Chicago, Ill.), 2020-02, Vol.80 (4_Supplement), p.GS4-03-GS4-03

2020

Volltextzugriff (PDF)

17-Gene Genomic Prostate Score Test Results in the Canary Prostate Active Surveillance Study (PASS) Cohort

Journal of clinical oncology, 2020-05, Vol.38 (14), p.1549-1557

2020

Volltextzugriff (PDF)

Patient-specific meta-analysis of 3 validation studies of the 12-gene colon cancer recurrence score assay for recurrence risk assessment after surgery with or without 5FU and oxaliplatin

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.3599-3599

2021

Volltextzugriff (PDF)

Adverse pathology as a predictor of distant metastasis and prostate cancer mortality with 20-year follow up

Journal of clinical oncology, 2021-02, Vol.39 (6_suppl), p.219-219

2021

Volltextzugriff (PDF)

1 – 25 von 48

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(46)
Mit Volltextzugriff
(44)

Publikationsform

Artikel
(47)
Dissertationen
(1)

Sprache

Englisch
(48)
Japanisch
(3)

Erscheinungsjahr

n.n

Thema

Science & Technology
(23)
Humans
(19)
Life Sciences & Biomedicine
(19)
Female
(12)
Male
(9)
Aged
(8)
Middle Aged
(8)
Mathematics
(7)
Oncology
(7)
Physical Sciences
(7)
Statistics & Probability
(7)
Biological And Medical Sciences
(5)
Proportional Hazards Models
(5)
Adult
(4)
Breast Cancer
(4)
Breast Neoplasms - Genetics
(4)
Gene Expression
(4)
Mathematical & Computational Biology
(4)
Medical Sciences
(4)
Prognosis
(4)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Development and Validation of a Tool Integrating the 21-Gene Recurrence Score and Clinical-Pathological Features to Individualize Prognosis and Prediction of Chemotherapy Benefit in Early Breast Cancer

Extensions of the absolute standardized hazard ratio and connections with measures of explained variation and variable importance

Reply to K. Ando et al

Long-term safety of a novel antianginal agent in patients with severe chronic stable angina : The Ranolazine Open Label Experience (ROLE)

Population-based estimate for the correlation of the Oncotype Dx Breast Recurrence Score® result and Ki-67 IHC MIB-1 pharmDx in HR+, HER2-, node-positive early breast cancer

Risk of Recurrence and Chemotherapy Benefit for Patients With Node-Negative, Estrogen Receptor–Positive Breast Cancer: Recurrence Score Alone and Integrated With Pathologic and Clinical Factors

Validating the association of adverse pathology with distant metastasis and prostate cancer mortality 20-years after radical prostatectomy

Gene identification using true discovery rate degree of association sets and estimates corrected for regression to the mean

Patient-specific Meta-analysis of 2 Clinical Validation Studies to Predict Pathologic Outcomes in Prostate Cancer Using the 17-Gene Genomic Prostate Score

Prospective Calculation of Identification Power for Individual Genes in Analyses Controlling the False Discovery Rate

21-Gene assay as predictor of chemotherapy benefit in HER2-negative breast cancer

GPS Assay Association With Long-Term Cancer Outcomes: Twenty-Year Risk of Distant Metastasis and Prostate Cancer-Specific Mortality

Whole transcriptome RNA-Seq analysis of breast cancer recurrence risk using formalin-fixed paraffin-embedded tumor tissue

Adjusting for covariates in evaluating markers for selecting treatment, with application to guiding chemotherapy for treating estrogen-receptor-positive, node-positive breast cancer

Patient-specific meta-analysis for risk assessment using multivariate proportional hazards regression

Generalizing the standardized hazard ratio to multivariate proportional hazards regression, with an application to clinical~genomic studies

Separate Class True Discovery Rate Degree of Association Sets for Biomarker Identification

Cytomegalovirus (CMV) DNA Load Is an Independent Predictor of CMV Disease and Survival in Advanced AIDS

Abstract GS4-10: Development and validation of a tool integrating the 21-gene recurrence score and clinicopathlogic features to individualize prognosis for distant recurrence and prediction of absolute chemotherapy benefit in early breast cancer

Correlation of the oncotype DX breast recurrence score and the ki-67 IHC MIB-1 pharmDX score in HR+, HER2-, node-positive early breast cancer

Interval Estimation of the Absolute Risk of an Event with Competing Risks Using Proportional Regression of Cause-Specific Hazards

Abstract GS4-03: Validation of the clinical treatment score post 5 years (CTS5) in women with hormone receptor positive, HER2-negative, node-negative disease from the TAILORx study

17-Gene Genomic Prostate Score Test Results in the Canary Prostate Active Surveillance Study (PASS) Cohort

Patient-specific meta-analysis of 3 validation studies of the 12-gene colon cancer recurrence score assay for recurrence risk assessment after surgery with or without 5FU and oxaliplatin

Adverse pathology as a predictor of distant metastasis and prostate cancer mortality with 20-year follow up

Suchergebnisse filtern